Routine Management
PreclinicalSmall molecule
Routine Management is one of 17 small molecule programs targeting Gastrointestinal Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Gastrointestinal Disease
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Entereg
Merck & Co.Approved
Cipro
BayerApproved
Tofranil
SanofiApproved
Bayer Aspirin
BayerApproved
Elavil
AstraZenecaApproved
Lexapro
AbbVieApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Routine Management. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSeton Healthcare Family